A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.

Johanna C. Bendell,Alexander I. Spira,Ramez N. Eskander,Ezra E.W. Cohen,Geoffrey Kuesters,Christopher Plescia,Karen Campbell,Tiffany Chen,Omid Hamid

A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.

2021

Johanna C. Bendell
Alexander I. Spira
Ramez N. Eskander
Ezra E.W. Cohen
Geoffrey Kuesters
Christopher Plescia
Karen Campbell
Tiffany Chen
Omid Hamid

TPS2664Background: High-risk strains of HPV (HPV 16/18) have been associated with the development of multiple cancers, and the associated viral antigens are validated targets from immunotherapy app...

Keywords:

Immunotherapy
Artificial antigen
Cancer research
Interleukin 12
Peptide
Cell
HLA-A
Medicine
Red blood cell
4-1BB ligand

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations